Sartorius Stedim BiotechSRTOY -0.30%82 Altman Z2-Score is 2.57 as of Jun. 29, 2026, which is 40% below its 10-year median of 4.25. GuruFocus rates SRTOY with a GF Score™ of 82/100 and a GF Value™ of $23.65 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 845 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 57.04% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Sartorius Stedim Biotech has a Altman Z2-Score of 2.57, indicating it is in Grey Zones. This implies that Sartorius Stedim Biotech is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Sartorius Stedim Biotech's Altman Z2-Score or its related term are showing as below:
SRTOY'
s Altman Z2-Score Range Over the Past 10 Years
Min: 2.42 Med: 4.25 Max: 5.88
Current: 2.57
During the past 13 years, Sartorius Stedim Biotech's highest Altman Z2-Score was 5.88. The lowest was 2.42. And the median was 4.25.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRTOY vs ISRG, BDX, MDLN: Altman Z2-Score Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Altman Z2-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Sartorius Stedim Biotech (SRTOY) has a Altman Z2-Score of 2.57 as of Jun. 29, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Sartorius Stedim Biotech and its competitors. This is 40% below median its historical median of 4.25. Over the past decade, Sartorius Stedim Biotech's Altman Z2-Score has ranged from 2.42 to 5.88. According to the industry distribution chart, Sartorius Stedim Biotech ranks #482 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 57%.
Is Sartorius Stedim Biotech's Altman Z2-Score too high?
Sartorius Stedim Biotech's current Altman Z2-Score of 2.57 is 40% below median its 10-year median of 4.25. Over the past 10 years, this metric has ranged from a low of 2.42 to a high of 5.88. The Medical Devices & Instruments industry median Altman Z2-Score is 3.48. Sartorius Stedim Biotech's value of 2.57 is 26.1% below this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #482 out of 845 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Altman Z2-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #482 out of 845 companies for Altman Z2-Score. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median Altman Z2-Score is 3.48. Sartorius Stedim Biotech's value of 2.57 is 26.1% below this benchmark. Historically, Sartorius Stedim Biotech's own Altman Z2-Score has ranged from 2.42 to 5.88 over the past decade. While the company's 10-year median is 4.25 vs. the industry median of 3.48, Sartorius Stedim Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.48, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Altman Z2-Score of 2.57 is 26.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Altman Z2-Score is 2.57, which is 40% below median its own 10-year median of 4.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.65, compared to a current price of $20.03 — trading 15.3% below its estimated fair value. The current Altman Z2-Score is 2.57, which is 40% below median its 10-year median of 4.25 and 26.1% below the Medical Devices & Instruments industry median of 3.48. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current Altman Z2-Score is 2.57 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $20.03 is trading 15.3% below its estimated GF Value™ of $23.65.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SRTOY:
Altman Z2-Score: 2.57 (40% below median its 10-year median of 4.25)
GF Value™: $23.65 vs. price of $20.03 (15.3% below fair value)
Industry Position: 26.1% below the Medical Devices & Instruments median (#482 of 845)
No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for SRTOY
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTOY has been successfully added to your 
